Objective
To evaluate whether the vascular endothelial growth factor (VEGF) pathway can be used as a target for effective treatment of pancreatic cancer.
Summary Background Data
VEGF and its receptors (VEGF-RI and -RII) are the predominant regulators of tumor neoangiogenesis, a key element for tumor growth and progression. However, VEGF receptor expression has been thought to be limited to endothelial cells, limiting the possibility of targeting it for therapy of pancreatic cancer.
Methods
Protein localization and mRNA were studied in pancreatic cancer specimens, normal pancreas, human pancreatic cancer cell lines, and an endothelial cell line. Cell proliferation was determined by [ 3 H] thymidine uptake. Both VEGF receptors were genetically eliminated by antisense technology. The same approach was used in a murine model of pancreatic cancer in a therapeutic approach.
Results
VEGF-RI mRNA and VEGF-RII mRNA were expressed in 17 and 15 of 24 pancreatic cancer samples, respectively. VEGF receptors were found not only in blood vessels but also in pancreatic cancer cells. VEGF-RII expression correlated with poor tumor differentiation and was associated with poorer survival, while VEGF-RI expression did not correlate. VEGF treatment led to extensive growth stimulation in six of seven pancreatic cancer cell lines, which was completely inhibited by antisense treatment against VEGF-RII. Liposome-mediated gene transfer in nude mice with pancreatic tumors markedly reduced local tumor growth and decreased metastatic tumor spread.
Conclusions
The VEGF/VEGF-RII pathway regulates angiogenesis and local tumor growth and spread in pancreatic cancer. Genetic targeting of VEGF-RII blocks local growth and metastatic spread of pancreatic cancer cells in vivo and therefore offers a potential new therapeutic option for patients with this disease.
Ductal adenocarcinoma of the exocrine pancreas accounts for more than 90% of malignant pancreatic tumors. 1, 2 Annually about 28,000 patients are diagnosed with pancreatic cancer in the United States, and almost the same number of patients die from this disease per year. 1, 3 Pancreatic cancer is the fourth leading cause of cancer-related deaths in Western countries in men and women and is among the deadliest diseases in humans. 1, 3 Aggressive local growth and early metastases are hallmarks of this disease, distinguishing this tumor from other types of adenocarcinomas. 1, 2 Extensive production of extracellular matrix proteins by pancreatic cancer produces a scirrhous tumor type. 4, 5 Because of this desmoplastic reaction, it is likely that pancreatic cancer grows in a "cancer-specific" microenvironment, which might influence the expression of certain genes. [5] [6] [7] Among those genes is vascular endothelial growth factor (VEGF), a central peptide in tumor neoangiogenesis, which is highly regulated by the tumor microenvironment, especially by low oxygen levels. 8 -10 VEGF not only triggers angiogenesis but also potently permeabilizes blood vessels. It therefore is a multifunctional protein that likely mediates tumor angiogenesis and affects metastasis, which is a clinical characteristic of human pancreatic cancer. 1,10 -12 At least two specific cell surface receptors, VEGF-RI (flt-1) and VEGF-RII (KDR, flk-1), participate in VEGF signaling. [13] [14] [15] [16] Both are expressed by endothelial cells or their progenitors, so VEGF was long considered to be a paracrine growth factor. 16, 17 Recent studies, however, suggest that VEGF possibly also acts in addition as an autocrine growth regulator. 18 -21 In the case of human pancreatic cancer, the role of VEGF and its receptors is not clear, since in contrast to Kaposi sarcoma, pancreatic cancer does not appear to be a highly vascularized tumor. 18, 22 What is known, however, is that VEGF is overexpressed in this highly aggressive cancer type and that human pancreatic cancer grows in a microenvironment of low oxygen, a condition that triggers VEGF gene expression. 22, 23 Because of the central function of VEGF, we analyzed the role of this peptide and its receptors VEGF-RI and VEGF-RII in human pancreatic cancer. Expression of VEGF and its receptors was analyzed in specimens of normal pancreatic tissue, from patients with pancreatic cancer, and in various pancreatic cancer cell lines. We show that the autocrine growth stimulation of VEGF is mediated by VEGF-RII, since an antisense oligonucleotide against VEGF-RII abrogated its mitogenic activity while antisense oligonucleotides against VEGF-RI did not. Liposome-mediated gene transfer of antisense oligonucleotide cocktail in vivo to induce VEGF-RII blockade markedly reduced tumorigenicity and invasiveness in an orthotopic xenograft model of pancreatic cancer.
METHODS

Human Pancreatic Cancer Specimens
Human pancreatic cancer tissues used for RNA extraction were obtained from 24 patients undergoing resection for pancreatic cancer at the University Hospitals of Bern (Bern, Switzerland) and the University of California at Los Angeles. Normal human pancreatic tissue specimens (nine male, six female) were obtained through an organ donor program and from normal pancreatic tissue obtained from patients who underwent pancreatic resection. The study protocol was approved by the Ethics Committee at the University of Bern, Switzerland, and by the Human Subjects Committee at the University of California at Los Angeles.
According to the Union Internationale Contre le Cancer (UICC) classification, there were 3 stage I, 7 stage II, 12 stage III, and 2 stage IV pancreatic adenocarcinomas. Routine pathologic grading resulted in 3 well-differentiated, 8 moderately differentiated, 11 poorly differentiated, and 2 undifferentiated pancreatic adenocarcinomas. Tissue samples for RNA extraction were frozen in liquid nitrogen immediately after removal in the operating room and stored at Ϫ80°C until further analysis.
For immunohistochemistry 47 tissue specimens, different from those used for Northern blot analysis, were analyzed (27 men, 20 women). Of these 47 patients one underwent preoperative chemotherapy for pancreatic cancer; the remaining 46 patients were not treated before resection. According to the TNM classification of the UICC, there were  6 patients with stage I, 13 with stage II, 24 with stage III,  and 4 with stage IV disease. Thirteen tumors were well differentiated (grade 1), 30 tumors were moderately differentiated (grade 2), and 4 tumors were poorly differentiated (grade 3). Freshly removed pancreatic tissue samples were immediately fixed in formalin solution for 12 to 24 hours and paraffin-embedded for routine histopathologic analysis and immunohistochemical analysis.
RNA Extraction and RT-PCR
Total RNA was extracted using the guanidine isothiocyanate-based RNeasy Kit (Quiagen, Hamburg, Germany) according to the manufacturer's instructions. The integrity of all mRNA preparations was confirmed by gel electrophoresis and amplification of housekeeping genes. One microgram total RNA was used for first-strand cDNA synthesis, which was done with random primers included in the firststrand cDNA synthesis kit according to the manufacturer's instructions (Roche Diagnostics, Mannheim, Germany). Reverse transcriptase products were amplified by polymerase chain reaction (PCR) using gene-specific primers based on the published human cDNA sequences VEGF (M32977), VEGF-RI (E13256), 15 and VEGF-RII (AF063658). 24 Amplification of human VEGF cDNA was done using the oligonucleotide sense primer 5'-GGAGTACCCTGAT-GAGATCGA-3' corresponding to bp ϩ42 to ϩ63 and the antisense primer 5'-GGACTGTTCTGTCGATGGTGA-3' corresponding to bp ϩ545 to ϩ566. For VEGF-RI expression, two primers located within the coding region were synthesized: 5'-CAA GTC GCC AGA GGC ATG GAG TT-3'corresponding to nucleotides ϩ3762 to ϩ3284, and the antisense primer 5'-GAT GTA GTC TTT ACC ATC GTC TTG-3'corresponding to the nucleotides ϩ3736 to ϩ3759. 15 VEGF-RII mRNA transcripts were amplified with sense primer 5'-GAG GGC CAC TCA TGG TGA TTG T-3' corresponding to bp ϩ2954 to ϩ2975 and the antisense primer 5'-TGC CAG CAG TCC AGC ATG GTC TG-3' corresponding to bp ϩ3640 to ϩ3662. 24 PCR amplification of cDNA was done in 35 cycles and yielded a 531-bp product of the human VEGF gene, a 498-bp product for VEGF-RI, and a 709-bp product for VEGF-RII. To ensure sequence identity, all three PCR fragments were cloned into a pGEM easy vector (Promega Corp., Madison, WI) and sequenced using the T7 RNA polymerase in the Sequencing Core Facility at UCLA. Furthermore, known positive controls as well as negative controls were included in every PCR experiment to minimize the risk of false-positive results due to carryover contamination. 
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Cell Culture
Seven human pancreatic cancer cell lines (AsPc-1, BxPC-1, Capan-1, Capan-2, HPAF-1, MIA PaCa-2, and PANC-1) were purchased from the American Tissue Type Culture Collection (ATCC, Rockville, MD). These cell lines were chosen because of their different degree of cellular differentiation. [25] [26] [27] [28] [29] The nontransformed human umbilical vein cell line (HUVEC) used in control experiments was cultured in complete EGM medium according to the vendor's instructions (Clonetics, San Diego, CA). All other cell lines were cultured either in RPMI (AsPc-1, BXPc-1, Capan-1, Capan-2, HPAF-1) or in DMEM (MIA PaCa-2 and PANC-1) supplemented with 10% heat-inactivated fetal bovine serum with penicillin G (100 U/mL) and streptomycin (100 g/mL) (Life Technology, Rockville, MD). All cell lines were grown through fewer than 10 passages, which was particularly critical for Capan-1 and HUVEC cells. Cells were grown as a monolayer at 37°C in humidified air with 5% (AsPc-1, BxPc-1, Capan-1, Capan-2, HPAF-2, HUVEC) or 10% CO 2 (MIA PaCa-2, PANC-1). Recombinant human VEGF was purchased from Sigma Chemicals (St. Louis, MO).
Antisense Oligonucleotides
Phosphorothiolated antisense oligonucleotides were purchased from Gibco (Life Technology). Each of the VEGF-RI and VEGF-RII antisense oligonucleotides was designed within two different regions within the coding sequence of both genes. The sequence and location of the VEGF-RI-AS1 was TAG CTG ACC ATG GTG AGC GCG CGC (bp ϩ235/260); the VEGF-RI-AS2 antisense oligonucleotide was AGT TAT GCT CAG CCT TTC GCT TTC (bp ϩ451/474). Antisense oligonucleotide against VEGF-RII-AS1 was GTC CAA GTC CCT CTG TCC CCT GCA (bp ϩ156/180) and against VEGF-RII-AS2 was AGC ACT TGT AGG CTC CAG TGT (bp ϩ290/310). In control experiments a scrambled oligonucleotide with the sequence SAS 5'-TAG CAT GAT ACC ACA TGG ATC-3' was used. To prove cellular uptake of antisense oligonucleotides and optimize delivery efficiency, especially in vivo, two additional 5'-FAM (5-carboxyfluorescein)-labeled oligonucleotides were synthesized and analyzed by fluorescence microscopy for in vitro and in vivo experiments. The sequence of the 5'-FAM-labeled oligonucleotides was identical to the previously described VEGF-RI-AS1 and VEGF-RII-AS1 oligonucleotides. In cell culture experiments oligonucleotides were used at a concentration of 5.0 mol/L delivered with cationic lipids (Lipofecase, Life Technology).
Cell Proliferation Assay
For [ 3 H] thymidine incorporation, all cell lines were seeded in 24-well plates at a density between 0.5 ϫ 10 4 and 2 ϫ 10 4 cells per well, depending on the growth rate of the different cell lines. Logarithmically growing cells were serum-deprived for 12 hours before stimulation with various doses of rhVEGF (1, 10, 25 ng/mL) for 16 hours. DNA was measured on day 5 by adding 5 Ci of [ 3 H] thymidine (Amersham Pharmacia Biotech, Piscataway, NJ) for 6 hours. Cells were then washed with phosphate-buffered saline and fixed with 5% TCA. Cells were lysed in 500 L of lysis base containing 0.1 N NaOH ϩ 1% SDS, and [ 3 H] thymidine incorporation was measured by liquid scintillation counting (Beckman Coulter Instruments, Fullerton, CA). The assays were done in triplicate and repeated twice. In the case of antisense experiments, phosphorothiolated antisense oligonucleotides were added 48 hours before VEGF stimulation.
Immunohistochemistry
Tissues from normal human pancreas and human pancreatic cancer were fixed in formalin and embedded in paraffin. Tissue sections (3 m) were deparaffinized and rehydrated as described previously. 30 Deparaffinization and rehydration for VEGF were done in a one-step procedure using Dewax solution (BioGenex Laboratories, San Ramon, CA) without target retrieval. For VEGF-RI, VEGF-RII, and CD31, target retrieval was done by pressure cooking at 97°C for 25 minutes in 0.1 mol/L sodium citrate buffer followed by a 5-minute treatment in a 3% hydrogen peroxide solution to block endogenous peroxidase activity. After blocking the slides in normal goat serum for 20 minutes, the primary antibody was added. In the case of VEGF, the antibody (Sigma) was diluted 1:20 in normal goat serum (Sigma). Antibodies to VEGF-RI and -II (Santa Cruz Biotechnology, Santa Cruz, CA) were diluted 1:100. Incubation was overnight at 4°C. For microvessel staining, the purified antimouse CD31 antibody (BD PharMingen, San Diego, CA) was used at a dilution of 1:40 and incubated overnight at 4°C. After thorough rinsing in TBS-Tween washing solution, slides were incubated with streptavidin-biotin for 25 minutes, followed by a 15-minute incubation with streptavidin peroxidase. For color development, slides were exposed to DAB (3,3'-diaminobenzidine tetrahydrochloride) (Sigma) for 5 minutes. Slides were counterstained with hematoxylin and mounted in permanent mounting medium.
In control experiments either the first or the second antibody was omitted. In these cases no immunopositivity was detectable. Unless indicated otherwise, all reagents for immunohistochemistry were purchased from Kirkegaard & Perry (Gaithersburg, MD). Stained tissue specimens were analyzed by two independent observers unaware of patient status. Positive immunostaining was defined as staining of at least 50% of tumor blood vessels or cancer cells, as previously reported. 22
Animal Studies
Five-week-old male nude mice (BALB/cA) weighing 18 to 22 g were used for subcutaneous and orthotopic tumor implantation. All animals were maintained on a daily 12hour light/dark cycle and housed in semisterile microisolator cages containing autoclaved bedding, with food and water ad libitum. The experimental protocol was approved by the Chancellor's Animal Research Committee of the University of California, Los Angeles, in accordance with the national guidelines for animal care and use of laboratory animals.
Tumor Induction in Nude Mice
Approximately 10 7 viable Capan-2 or MIA PaCa-2 cells were injected subcutaneously for tumor induction in nude mice. After 4 weeks of subcutaneous tumor growth, a tumor fragment 1 mm in diameter was removed from the subcutaneous tumor and transplanted into the tail of the pancreas for the actual study. 31 Experimental conditions were standardized and all animals received the same subcutaneous tumor at the same time. Then mice were randomly assigned either to receive antisense oligonucleotide treatment (two treatment groups, 10 per group) or to the two sham-treated control groups (10 per group). Orthotopic transplantation was performed as described elsewhere. 32 Briefly, a subcostal laparotomy was performed and the pancreas exteriorized. A small pancreatic parenchymal pocket was created and one small piece of 1 ϫ 1-mm tumor was implanted into the tissue without any need to further anchor the transplant. After the pancreas was returned to the abdomen, the peritoneal incision was closed with 6-0 Prolene (Ethicon, Somerville, NJ) and separately the abdominal wall and skin were closed using 5-0 Vicryl (Ethicon). After tumor transplantation, the mice were inspected daily. The growth rate of the tumor was monitored by abdominal palpation, and the tumor volume was determined after the animal was killed.
Treatment of Established Tumor Xenografts
Four weeks after the tumor was transplanted into the pancreas, antisense oligonucleotide application was initiated. The antisense mixture was slowly injected into the tail vein of the nude mice at a dosage of 20 nmol/mouse (body weight approximately 25 g) three times per week for 6 weeks, with no apparent side effects. Three days after the last treatment, all animals were killed. Animals in the control group received the same concentration of a scrambled oligonucleotide cocktail (SAS) delivered in cationic lipids.
Tumor Assessment
Ten weeks and 3 days after orthotopic tumor induction, the mice were killed. In the case of severe tumor disease (ascites, tumor size Ͼ 1 cm, cachexia) animals were killed earlier. All animals underwent a complete examination of the thoracic and abdominal cavity. The volume of ascites was quantified with an Eppendorf laboratory pipette (Eppendorf, Hamburg, Germany) when the animals were killed. The "primary" tumor was measured in three dimensions, and tumor volume was calculated using the formula: tumor volume ϭ length ϫ width ϫ depth. Possible metastatic tumor spread was determined macroscopically at autopsy in all thoracic, abdominal, retroperitoneal, and pelvic organs. All macroscopically suspicious lesions were analyzed by microscopic examination. All metastatic lesions in different organs were counted and each different organ was assigned 1 point. Therefore, every point in the metastatic score represented a different organ of metastatic tumor spread.
Immunohistochemistry for Neoangiogenesis in the Nude Mouse Model
Xenografted tumors were fixed in formalin and embedded in paraffin. Tissue sections (3 m) were deparaffinized and rehydrated as described previously. 30 For microvessel staining, target retrieval was done by pressure cooking at 97°C for 25 minutes in 0.1 mol/L sodium citrate buffer followed by a 5-minute treatment in a 3% hydrogen peroxide solution to block endogenous peroxidase activity. After blocking the slides in normal goat serum for 20 minutes, biotinylated antimouse CD31 antibody (BD PharMingen) was added at a dilution of 1:40 and incubated overnight at 4°C. After thorough rinsing in TBS-Tween washing solution, slides were incubated with streptavidin-biotin for 25 minutes, followed by a 15-minute incubation with streptavidin peroxidase. For color development DAB (3,3'-diaminobenzidine tetrahydrochloride) (Sigma) was used for 5 minutes. Slides were counterstained with hematoxylin and mounted in permanent mounting medium. In control experiments, either the first or the second antibody was omitted. In these cases no immunopositivity was detectable. Unless indicated otherwise, all reagents for immunohistochemistry were purchased form Kirkegaard & Perry. Stained tissue specimens were analyzed by two independent observers unaware of the animal's status. Positive immunostaining was defined as previously reported. 22 Microvessel density was determined as described by Weidner. 33, 34 The highest area of vascularization was determined by scanning the slide at low-power magnification. Microvessel density was determined by counting stained vessels in ten 200ϫ fields (0.74 mm 2 /field).
Statistical Analysis
Unless indicated, results are expressed as means Ϯ SE of at least three different experiments. A two-tailed value of P Ͻ .05 was considered statistically significant. For statistical analysis, the Student t test and the chi-square test were used. The duration of postoperative survival was computed by the Kaplan-Meier method and compared by the log-rank test according to Mantel-Haenszel.
RESULTS
VEGF, VEGF-RI, and VEGF-RII
Expression in Human Tissue Specimens
Expression of the angiogenic system consisting of the ligand VEGF and its two cell surface receptors (VEGF-RI 
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and -RII) in human pancreatic cancer specimens compared with the normal controls was assessed by Northern blot analysis. VEGF mRNA was markedly upregulated in the human pancreatic cancer samples. 22 Twenty-two of 24 (92%) pancreatic cancer samples showed increased VEGF mRNA levels (Fig. 1 ). In the normal pancreatic tissue specimens, neither VEGF-RI nor VEGF-RII mRNA was detectable. In contrast, 17 of 24 (71%) pancreatic cancer tissues exhibited enhanced VEGF-RI mRNA levels, and in 15 of 24 (63%) pancreatic cancer tissues VEGF-RII mRNA was upregulated.
Further analysis of the expression data with clinicopathologic parameters indicated a significant relationship between VEGF-RII mRNA expression levels and tumor grading (Table 1) . Thus, poorly differentiated and undifferentiated tumors had significantly higher VEGF-RII mRNA levels than well-differentiated and moderately differentiated tumors. In contrast, no relationship between VEGF mRNA or VEGF-RI mRNA levels and tumor grading was found. In addition, no correlation was found between VEGF mRNA expression levels and the expression levels of either VEGF-RI or VEGF-RII mRNA.
Localization of VEGF in Normal Pancreas and Pancreatic Cancer
In the normal pancreas only faint VEGF immunoreactivity was detectable in islets of Langerhans (Fig. 2) . No immunoreactivity was present in acinar or ductal cells in the normal pancreas. In contrast, enhanced immunoreactivity for VEGF was observed in the pancreatic cancer samples. VEGF immunoreactivity was strongly present in pancreatic cancer cells and in endothelial cells of blood vessels within the tumor or adjacent to the tumor mass. In addition, strong VEGF immunoreactivity was diffusely present within the extracellular matrix of pancreatic cancer specimens. Pancreatic islets within and adjacent to the tumor exhibited similar VEGF immunoreactivity as in the normal controls.
Localization of VEGF-RI and VEGF-RII in Normal Pancreas and Pancreatic Cancer
Since VEGF binds primarily to the two cell surface receptor tyrosine kinases VEGF-RI (data not shown) and VEGF-RII ( Fig. 3) , immunohistochemistry for both receptor types was performed to determine their exact cellular localization.
In the normal pancreas, VEGF-RI and VEGF-RII immunoreactivity was present in the islets of Langerhans but was absent in acinar and ductal cells. Blood vessels in the normal pancreas did not exhibit any VEGF-RI or VEGF-RII immunoreactivity. In contrast, pancreatic cancer cells showed moderate VEGF-RI and VEGF-RII immunoreactivity. Cancer tissue showed a strong immunoreactivity for both receptors in blood vessels in the majority of tumors. Expression of VEGF-RII was abundantly and consistently present in vascular hot spots. Immunoreactivity for both receptor types was found in a minority of already wellestablished tumor vessels. There was no difference in VEGF-RI and VEGF-RII immunoreactivity in islet cells in specimens from cancer patients compared with normal controls.
Relation Between Molecular Findings and Survival
The mean postoperative survival for all the pancreatic cancer patients in this series was 10.5 Ϯ 1.1 months. Thirtyone of 47 specimens tested positive for VEGF-RI. No relationship between survival and VEGF-RI immunopositivity was found. In the case of VEGF-RII expression, 26 of 47 specimens exhibited immunopositivity (Fig. 4) . Three of the 13 well-differentiated tumor specimens stained positive 
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Analysis of VEGF, VEGF-RI, and VEGF-RII mRNA Expression in Pancreatic Cancer Cell Lines
VEGF, VEGF-RI, and VEGF-RII mRNA expression was studied in seven different human pancreatic cancer cell lines and one normal human endothelial cell line (HUVEC) by RT-PCR ( Fig. 5 ). VEGF mRNA transcripts were detectable in all human pancreatic cancer cell lines tested, although VEGF receptor mRNA expression has been thought to be restricted to endothelial cells or their progenitors. VEGF-RI transcripts were detectable in five of seven pancreatic cancer cell lines and VEGF-RII expression was detectable in six of seven human pancreatic cancer cell lines. In the control experiments, HUVEC cells consistently expressed VEGF, VEGF-RI, and VEGF-RII mRNA.
VEGF is a Novel Mitogen in Pancreatic Cancer
Because VEGF receptors were detectable in most human pancreatic cancer cell lines and immunopositivity for both receptors was seen on cancer cells of the human tumor specimens, we analyzed whether VEGF directly stimulates the growth of pancreatic cancer cells. Six of seven pancreatic cancer cell lines tested showed a strong mitogenic response on VEGF stimulation (Fig. 6) . The VEGF dosages that stimulated growth of pancreatic cancer cells were comparable to the dosages required to stimulate HUVEC cells. The highest mitogenic response was seen at a VEGF dosage of 10 ng/mL, which was also the dosage achieving maximal mitogenic response in HUVEC cells. Even with the lowest VEGF dosage of 1 ng/mL medium, a significant increase in [ 3 H] thymidine incorporation was seen in the AsPc-1, Capan-2, HPAF-2, and MIA PaCa-2 cancer cells. Dose escalation to 25 ng/mL medium did not result in a further increase in DNA synthesis. The only human pancreatic cancer cell line that did not respond to VEGF stimulation was PANC-1, the cell line that did not express VEGF-RII mRNA.
Mitogenic Activity of VEGF on Human Pancreatic Cancer Cells Is Mediated by VEGF-RII
Loss of function experiments were done to further determine which of the two VEGF receptors mediates the mitogenic activity on VEGF stimulation and thereby mediates autocrine pancreatic cancer cell growth. Two different phosphorothiolated antisense oligonucleotides were synthesized . Kaplan-Meier curves for patients in whom the tumors exhibited positive VEGF-RII immunostaining (n ϭ 26, solid line) compared with patients in whom the tumor tested negative for VEGF-RII on immunohistochemistry (n ϭ 21, broken line). Log-rank analysis of the postoperative survival periods indicates that patients whose tumors did not express VEGF-RII immunoreactivity lived significantly longer (P Ͻ .01) than those whose tumors expressed VEGF-RII. for each receptor.
In control experiments, all tested human pancreatic cancer cell lines showed intense cellular uptake of 5'-FAM-modified oligonucleotides. However, when a cationic transfer reagent (Lipofecase, Life Technology) was used, approximately 13-fold higher oligonucleotide uptake was detected (data not shown). Addition of antisense oligonucleotides targeting VEGF-RI (VEGF-RI-AS1 and VEGF-RI-AS2) or a cocktail consisting of VEGF-RI-AS1 and VEGF-RI-AS2 did not alter the mitogenic activity of VEGF. In contrast, addition of VEGF-RII antisense oligonucleotides VEGF-RII-AS1 and VEGF-RII-AS2 reduced the mitogenic activity of VEGF on the pancreatic cancer cell lines (Fig. 7) . The highest suppression of VEGF-mediated cancer cell proliferation was seen when both VEGF-RII antisense oligonucleotides (VEGF-RII-AS1 and VEGF-RII-AS2) were used as a cocktail. 
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Effect of VEGF-RII Antisense Oligonucleotide Treatment on Pancreatic Cancer Cell Growth In Vivo
For in vivo studies, an orthotopic model for pancreatic cancer in nude mice was used. Since the combination of both oligonucleotides for VEGF-RII (VEGF-RII-AS1, VEGF-RII-AS2) showed the highest antiproliferative activity in vitro, we used both antisense oligonucleotides as a cocktail as described in Methods. Four weeks after tumor transplantation and pancreatic tumor manifestation, VEGF-RII oligonucleotide antisense treatment was initiated.
Antisense therapy in vivo using VEGF-RII antisense oligonucleotides (VEGF-RII-AS1 and -AS2) resulted in tumor growth control in both types of xenograft tumors (MIA PaCa-2 and Capan-2) (Fig. 8) . The growth-suppressive efficiency was higher in tumors derived from the more differentiated and slower-growing Capan-2 cell line compared with the undifferentiated and faster-growing tumors of the MIA PaCa-2 cell line, which in the sham-treated animals vigorously invaded into peripancreatic organs and regularly led to generalized intraabdominal tumor dissemination. Infiltration into peripancreatic organs (e.g., stomach, liver, and spleen) was significantly suppressed in animals treated with the antisense cocktail ( Table 2 ). Intraabdominal metastatic tumor dissemination was also reduced on antisense application; however, no difference was seen in the rate of extraabdominal metastases, as assayed in the lung parenchyma and thoracal lymph nodes.
Microvessels as a Potential Therapeutic Target
Since VEGF and its receptors are key peptides in the process of tumor neoangiogenesis, we tested whether functional receptor blockade of the angiogenic cytokine VEGF was accompanied by a reduced number of blood vessels. 
DISCUSSION
The angiogenic system of VEGF and its receptors VEGF-RI and -RII has been linked to the formation of new blood vessels in both malignant and nonmalignant conditions. 17, 35, 36 For many years it was accepted that this system was a typical example for paracrine growth modulation. VEGF was considered to be a selective mitogen for endothelial cells, since expression of VEGF receptors was thought to be restricted to endothelial cells or its progenitors. 16 Four VEGFbinding receptors have been identified; 15,37-39 among them, VEGF-RII (KDR, flk-1) appears to be the most significant because it mediates VEGF's mitogenic effects on endothelial cells, whereas VEGF-RI mediates endothelial cell migration. 16, 17 Expression of VEGF is upregulated in human pancreatic cancer, 40 a scirrhous cancer that likely grows in a microenvironment of low oxygen, a condition previously shown to be a strong stimulator for VEGF production in this disease. 41 Therefore, the tumor microenvironment found in human pancreatic cancer might stimulate VEGF expression independently from other oncogenic alterations, thus selecting VEGF rather than other growth factors. However, one requirement for VEGF signaling is the presence of VEGF receptors, of which little is known in pancreatic cancer. 22, 41, 42 In the present study VEGF and its receptors were found to be markedly overexpressed in human pancreatic cancer specimens. Apart from cancer cells, VEGF was also present in endothelial cells of tumor blood vessels, where both receptors were also detectable. However, only VEGF-RII was regularly found in so-called vascular hot spots.
In addition, strong VEGF immunoreactivity was present in the extracellular matrix, where preferentially the larger isoforms of VEGF, which contain both the heparin and heparan-sulfate binding motifs, are sequestered, stored, and released in biologically active form. 43, 44 The islets of Langerhans were also found to express both VEGF and its receptors, an observation that has already been described and linked to the distinctive architecture of blood vessels within the endocrine pancreas. 20, [45] [46] [47] While there are only a few reports that VEGF receptors are expressed by cancer cells, 18, 21, 48 this observation is not unexpected since cancer cells often lose their cellular differentiation with reappearance of an embryonic gene expression profile, a condition in which the receptors for VEGF have been described on pancreatic cells. 46, 47, 49 The findings of our study are in concordance with a recently published study in which the use of dominant negative VEGF-RII mutants inhibited the growth of pancreatic cancer cells. 42 Expression of VEGF-RII seems to be of clinical importance in pancreatic cancer, since expression of this receptor correlated with tumor differentiation and survival in otherwise comparable groups of patients with no apparent difference in postoperative tumor therapy. Well-differentiated pancreatic cancer specimens did not exhibit high levels of VEGF-RII mRNA expression, whereas less-differentiated tumors had higher mRNA levels for this protein. A relationship with clinicopathologic parameters was not seen for VEGF-RI expression. Therefore, the function of VEGF-RI in the growth of human pancreatic cancer remains speculative but could be associated with tumor cell migration, similar to the function of this receptor in endothelial cells, where VEGF-RI exerts a chemoattractant function. Overexpression of VEGF mRNA was seen in almost all cancer specimens without any obvious correlation to tumor stage or differentiation, most likely representing a common condition in the growth of human pancreatic cancer in a hypoxic tumor microenvironment.
The presence of VEGF receptors on pancreatic cancer cells raises the question of the functions of VEGF and its receptors other than angiogenesis in this malignancy. 50 Because the presence of ligand and receptors on the same cell type would define an autocrine loop, we tested whether VEGF acts as an autocrine growth factor in this disease. In vitro experiments on cultured pancreatic cancer cells revealed a dose-dependent growth stimulation with dosages that are required to stimulate endothelial cell proliferation. Thus, we demonstrated that VEGF acts as a strong mitogen in pancreatic cancer and that VEGF receptors are present on most pancreatic cancer cells.
Although VEGF-RI and -RII are expressed on pancreatic cancer cells, the mitogenic activity of VEGF is mediated by the expression of VEGF-RII. Loss of function experiments done with two specifically designed antisense oligonucleotides against both types of VEGF receptors proved that oligonucleotides against VEGF-RII abrogated the mitogenic activity of VEGF, whereas blockade of the VEGF-RI did not show antimitogenic activity. This observation was also confirmed in an orthotopic model for pancreatic cancer. Application of antisense oligonucleotides for VEGF-RII significantly reduced pancreatic cancer cell growth in vivo. Local tumor growth control was especially pronounced in well-differentiated Capan-2 tumors, since they exhibit more angiogenesis, and these tumors contain few necrotic tumor areas and grow slowly enough to allow neoangiogenesis to occur. In contrast, MIA PaCa-2 cells grew around extensive necrosis and probably grew too fast to form functional new blood vessels. However, VEGF-RII blockade reduced peripancreatic tumor infiltration and intraabdominal tumor seeding of MIA PaCa-2 tumors, but not the formation of thoracic metastasis; this could be because most of the lung metastases were microscopic and therefore likely not yet angiogenesis-dependent. It is difficult to judge whether the antiangiogenic activity or the direct antimitotic effect of VEGF-II antisense oligonucleotides was the leading cause for the differences seen in tumor growth, but it likely was due to both. Xenografted Capan-2 tumors treated with VEGF-RII antisense oligonucleotides had fewer tumor blood vessels than xenografted tumors of the sham-treated animals. In contrast, MIA PaCa-2 tumors treated with VEGF-RII antisense oligonucleotides showed no difference in tumor blood vessel density compared with sham-treated animals, but the antimitogenic activity of VEGF-RII antisense therapy in vitro was more pronounced.
Identification of VEGF as an autocrine growth factor in human pancreatic cancer expands our understanding of the distinctive biology of this tumor entity. Since human pancreatic cancer grows in an hypoxic tumor microenvironment, which permanently stimulates expression of VEGF, identification of receptor expression on human pancreatic cancer cells defines a new self-maintaining autocrine growth loop that not only guarantees a supply of tumor blood vessels but also increases the growth of pancreatic cancer cells directly. This dual axis (mitogenic and angiogenic) is of great interest for future clinical studies, since a number of novel therapeutics potentially disrupt the VEGF signaling pathway and therefore represent a possible treatment option for pancreatic cancer patients.
Discussion
DR. R. C. G. RUSSELL: This well-presented paper elucidates recent information on VEGF-RII in pancreatic cancer. The study shows for the first time VEGF-RII in both pancreatic cancer cells and cells within the islets of Langerhans. I would be grateful if you could reassure me that there is no cross-reactivity of your staining technique and that positive immunostaining in the islets is in the cells and not in the profuse blood vessels of the islet.
You have shown that there was a relationship between VEGF-RII and survival, particularly noted in the group with high-grade tumors. In order to determine the role of VEGF-RII we need to know whether the poorprognosis patients had an increase in the microvascular density; this would confirm the work you showed in the experimental studies.
Pancreatic cancer has been shown to be affected by growth factors, for instance gastrin, and inhibited by antigastrin or synthetic gastrin receptor blocking agents such as gastrozole. Do you think that the action of VEGF-RII is a specific antitumor effect or a nonspecific cellular environmental change-in other words an epiphenomenon? DR. P. BÜ CHLER: Thank you very much for your excellent comments. Let me start with the first question regarding the positive immunostaining in the islets of Langerhans. There are actually a couple of papers published in which exactly the same staining pattern was described, for VEGF and receptors. The authors concluded that it may be related to the rich vascular system within the islets, likely with a neoangiogenic stimulus. The reasons are unclear why this ongoing neoangiogenic stimulus is maintained in the endocrine pancreas, but Flk-1 staining within the islets of Langerhans had been confirmed.
It is true that positive VEGF-RII staining of pancreatic cancer cells is a new finding. This refers to the third question, whether it may only be an epiphenomenon. I do not think so. VEGF receptor expression was expected to be restricted to endothelial cells or their progenitors, so cancer cells should not be positive. One reason for their positivity could be that in undifferentiated tumor cells, an embryonic gene expression profile may reappear, which would be consistent with published observations that VEGF receptor is expressed in the developing pancreas. Therefore, I am convinced that VEGF receptor expression is not an epiphenomenon but part of the general genetic instability and part of the malignant genetic transition during the process of tumor cell redifferentiation.
Answering your second question, regarding a possible correlation between microvessel density and VEGF-RII positivity, the answer in our study is no. We stained 47 tumor samples with anti-Factor VIII antibodies and found that there was no correlation.
DR. R. POON: I think, following the first question raised by Dr. Russell, it is very important that your finding about the direct effect of VEGF on the cancer cell itself be clarified because so far from the literature, VEGF is known as a specific endothelial cell stimulator only. It only stimulates proliferation of endothelial cells. As far as I know, it has never been properly reported that VEGF stimulates cancer cell proliferation. Immunohistochemical staining is, after all, a very nonspecific technique in localizing the protein expression in the cancer. So I would suggest that if you really think that VEGF may have an effect on cancer cells, you should further confirm it with more specific localizing studies-for example, using laser capture microdissection to dissect out the cancer cells from the endothelial cells of the specimens. This would help you to confirm whether VEGF receptor II is really expressed in the cancer cells. DR. P. BÜ CHLER (closing): I completely agree with your comments. This is an elegant way of confirming our current observations, and we would like to do exactly what you suggest. 
